Mequon’s Titan Spine reports growth

News Graphic Staff

August 15, 2017

MEQUON — Titan Spine, with headquarters in Mequon, reported several second-quarter milestones. They include:

Surpassing 50,000 implantations of its Endoskeleton interbody fusion devices since inception

An increase of 42 percent in nanoLOCK sales volume since the close of the first quarter

Utilization of nanoLOCK by 150 surgeons in 98 hospitals

A total of 2,500 implantations of nanoLOCK since the product’s launch Titan Spine, 6140 W. Executive Drive, is a medical device surface technology company focused on developing innovative spinal interbody fusion implants, according to a news release.

“Following a record first quarter, we continued to exceed expectations during the second quarter for a strong close to the mid-2017 mark,” Chief Commercial Officer Ted Bird said in the news release. “The significant demand for nanoLOCK is a direct reflection of our expanded sales team’s ability to reach more surgeons and surgeons’ recognition of the advantages our surface technology provides at the nano-cellular level for patients heal faster following spine fusion surgery.

“In fact, we have more than doubled the number of surgeon customers using nanoLOCK in the second quarter compared to the first,” he added. “We are pleased that our second-quarter achievements demonstrate a growing confidence and continued adoption of nanoLOCK.”

Steve Cichy, executive vice president of sales, added, “The demand for nanoLOCK has certainly fueld our significant sales growth over the first half of this year. We have recently invested significant capital to beef up our instrument set and implant inventory to meet this growing demand, which will start to pay dividends over the remainder of the year and beyond.”

Titan Spine offers a full line of Endoskeleton titanium implants that feature its proprietary nanoLOCK surface technology, which was launched in the United States in October 2016. The U.S. Food and Drug Administration gave clearance for the product in late 2014, according to the news release.

The nanoLOCK surface technology consists of a combination of roughened topographies at the macro, micro and nano levels. The combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process, the news release added.

Titan Spine, which also is located in Germany, markets a full line of Endoskeleton interbody devices featuring its proprietary textured surface in the United States and portions of Europe through its sales force and network of independent distributors.